I-MAB Biopharma and AGC Biologics Partner on Late-Phase Project
AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), announced a new partnership with I-MAB Biopharma. AGC Biologics will manufacture the materials of I-MAB treatment at its site in Seattle, while also supporting the launch readiness of I-MAB’s product.
The Seattle cell culture facility is designed for capacity and technological flexibility, and has an extensive variety of single-use and stainless steel systems that meet the latest guidelines required for cGMP compliance. Besides, it has also undergone successful inspections by FDA and approved for commercial production making it an ideal location to support I-MAB goals to bring its treatment to the next clinical phase.
Jean-Baptiste Agnus, Chief Business Officer of AGC Biologics said, “We look forward to partnering with a true pioneer in innovative clinical research and development, and working together to help bring I-MAB’s product through the final clinical stages and to commercialization.”